O	0	1	A	A	DT	B-NP
O	2	7	novel	novel	JJ	I-NP
O	8	12	role	role	NN	I-NP
O	13	15	of	of	IN	B-PP
O	16	30	thrombospondin	thrombospondin	NN	B-NP
O	30	31	-	-	HYPH	B-NP
O	31	32	1	1	CD	I-NP
O	33	35	in	in	IN	B-PP
B-Multi-tissue_structure	36	44	cervical	cervical	JJ	B-NP
O	45	59	carcinogenesis	carcinogenesis	NN	I-NP
O	59	60	:	:	:	O
O	61	68	inhibit	inhibit	VB	B-VP
B-Tissue	69	75	stroma	stroma	NN	B-NP
O	76	84	reaction	reaction	NN	I-NP
O	85	87	by	by	IN	B-PP
O	88	98	inhibiting	inhibit	VBG	B-VP
O	99	108	activated	activate	VBN	B-NP
B-Cell	109	120	fibroblasts	fibroblast	NNS	I-NP
O	121	125	from	from	IN	B-PP
O	126	134	invading	invade	VBG	B-VP
B-Cancer	135	141	cancer	cancer	NN	B-NP
O	141	142	.	.	.	O

O	143	157	Thrombospondin	Thrombospondin	NN	B-NP
O	158	159	(	(	(	O
O	159	162	TSP	TSP	NN	B-NP
O	162	163	)	)	)	O
O	163	164	-	-	HYPH	B-NP
O	164	165	1	1	CD	I-NP
O	165	166	,	,	,	O
O	167	168	a	a	DT	B-NP
O	169	175	potent	potent	JJ	I-NP
O	176	188	angiogenesis	angiogenesis	NN	I-NP
O	189	198	inhibitor	inhibitor	NN	I-NP
O	198	199	,	,	,	O
O	200	203	has	have	VBZ	B-VP
O	204	208	been	be	VBN	I-VP
O	209	214	shown	show	VBN	I-VP
O	215	217	to	to	TO	I-VP
O	218	223	exert	exert	VB	I-VP
O	224	233	different	different	JJ	B-NP
O	234	244	biological	biological	JJ	I-NP
O	245	254	functions	function	NNS	I-NP
O	255	257	on	on	IN	B-PP
O	258	265	various	various	JJ	B-NP
B-Cell	266	270	cell	cell	NN	I-NP
O	271	276	types	type	NNS	I-NP
O	276	277	.	.	.	O

O	278	282	Here	Here	RB	B-ADVP
O	282	283	,	,	,	O
O	284	286	we	we	PRP	B-NP
O	287	298	investigate	investigate	VBP	B-VP
O	299	302	the	the	DT	B-NP
O	303	307	role	role	NN	I-NP
O	308	310	of	of	IN	B-PP
O	311	314	TSP	TSP	NN	B-NP
O	314	315	-	-	HYPH	B-NP
O	315	316	1	1	CD	I-NP
O	317	319	in	in	IN	B-PP
B-Cancer	320	325	tumor	tumor	NN	B-NP
O	325	326	-	-	HYPH	I-NP
B-Tissue	326	332	stroma	stroma	NN	I-NP
O	333	341	reaction	reaction	NN	I-NP
O	341	342	,	,	,	O
O	343	348	which	which	WDT	B-NP
O	349	351	is	be	VBZ	B-VP
O	352	358	mainly	mainly	RB	I-VP
O	359	372	characterized	characterize	VBN	I-VP
O	373	375	by	by	IN	B-PP
B-Cell	376	386	fibroblast	fibroblast	NN	B-NP
O	387	397	activation	activation	NN	I-NP
O	398	400	to	to	TO	B-VP
O	401	407	create	create	VB	I-VP
O	408	409	a	a	DT	B-NP
O	410	420	permissive	permissive	JJ	I-NP
O	421	437	microenvironment	microenvironment	NN	I-NP
O	438	441	for	for	IN	B-PP
B-Cancer	442	447	tumor	tumor	NN	B-NP
O	448	459	progression	progression	NN	I-NP
O	459	460	.	.	.	O

O	461	481	Immunohistochemistry	Immunohistochemistry	NN	B-NP
O	482	494	examinations	examination	NNS	I-NP
O	495	497	in	in	IN	B-PP
O	498	501	the	the	DT	B-NP
O	502	507	human	human	JJ	I-NP
B-Cancer	508	516	surgical	surgical	JJ	I-NP
I-Cancer	517	526	specimens	specimen	NNS	I-NP
O	527	531	have	have	VBP	B-VP
O	532	537	shown	show	VBN	I-VP
O	538	542	that	that	IN	B-SBAR
O	543	544	a	a	DT	B-NP
O	545	559	downregulation	downregulation	NN	I-NP
O	560	562	of	of	IN	B-PP
O	563	566	TSP	TSP	NN	B-NP
O	566	567	-	-	HYPH	B-NP
O	567	568	1	1	CD	I-NP
O	569	575	during	during	IN	B-PP
O	576	579	the	the	DT	B-NP
O	580	591	progression	progression	NN	I-NP
O	592	594	of	of	IN	B-PP
B-Multi-tissue_structure	595	603	cervical	cervical	JJ	B-NP
O	604	618	carcinogenesis	carcinogenesis	NN	I-NP
O	619	622	was	be	VBD	B-VP
O	623	634	accompanied	accompany	VBN	I-VP
O	635	637	by	by	IN	B-PP
O	638	640	an	an	DT	B-NP
O	641	650	emergence	emergence	NN	I-NP
O	651	653	in	in	IN	B-PP
O	654	657	the	the	DT	B-NP
O	658	670	upregulation	upregulation	NN	I-NP
O	671	673	of	of	IN	B-PP
B-Tissue	674	680	stroma	stroma	NN	B-NP
O	681	688	markers	marker	NNS	I-NP
O	688	689	,	,	,	O
O	690	695	alpha	alpha	SYM	B-NP
O	695	696	-	-	HYPH	B-NP
O	696	702	smooth	smooth	JJ	I-NP
O	703	709	muscle	muscle	NN	I-NP
O	710	715	actin	actin	NN	I-NP
O	716	717	(	(	(	O
O	717	722	alpha	alpha	SYM	O
O	722	723	-	-	HYPH	O
O	723	726	SMA	SMA	NN	B-NP
O	726	727	)	)	)	O
O	728	731	and	and	CC	O
O	732	738	desmin	desmin	NN	B-NP
O	738	739	.	.	.	O

O	740	752	Transfection	Transfection	NN	B-NP
O	753	755	of	of	IN	B-PP
B-Cell	756	760	SiHa	SiHa	NN	B-NP
I-Cell	761	769	cervical	cervical	JJ	I-NP
I-Cell	770	776	cancer	cancer	NN	I-NP
I-Cell	777	782	cells	cell	NNS	I-NP
O	783	787	with	with	IN	B-PP
O	788	789	a	a	DT	B-NP
B-Cellular_component	790	797	plasmid	plasmid	NN	I-NP
O	798	808	expressing	express	VBG	B-VP
O	809	812	the	the	DT	B-NP
O	813	816	TSP	TSP	NN	I-NP
O	816	817	-	-	HYPH	B-NP
O	817	818	1	1	CD	I-NP
O	819	826	protein	protein	NN	I-NP
O	827	836	exhibited	exhibit	VBD	B-VP
O	837	851	antiangiogenic	antiangiogenic	JJ	B-NP
O	852	860	activity	activity	NN	I-NP
O	861	863	in	in	FW	B-ADVP
O	864	869	vitro	vitro	FW	I-ADVP
O	870	873	and	and	CC	O
O	874	882	resulted	result	VBD	B-VP
O	883	885	in	in	IN	B-PP
O	886	893	reduced	reduce	VBN	B-NP
B-Cancer	894	899	tumor	tumor	NN	I-NP
O	900	906	growth	growth	NN	I-NP
O	907	909	in	in	IN	B-PP
O	910	916	severe	severe	JJ	B-NP
O	917	925	combined	combined	JJ	I-NP
O	926	942	immunodeficiency	immunodeficiency	NN	I-NP
O	943	944	(	(	(	O
O	944	948	SCID	SCID	NN	B-NP
O	948	949	)	)	)	O
O	950	954	mice	mouse	NNS	B-NP
O	954	955	,	,	,	O
O	956	961	which	which	WDT	B-NP
O	962	965	was	be	VBD	B-VP
O	966	977	accompanied	accompany	VBN	I-VP
O	978	980	by	by	IN	B-PP
O	981	982	a	a	DT	B-NP
O	983	991	decrease	decrease	NN	I-NP
O	992	994	in	in	IN	B-PP
B-Cancer	995	1000	tumor	tumor	NN	B-NP
O	1001	1016	vascularization	vascularization	NN	I-NP
O	1017	1020	and	and	CC	O
O	1021	1026	lower	low	JJR	B-NP
O	1027	1038	expressions	expression	NNS	I-NP
O	1039	1041	of	of	IN	B-PP
O	1042	1047	alpha	alpha	SYM	B-NP
O	1047	1048	-	-	HYPH	I-NP
O	1048	1051	SMA	SMA	NN	I-NP
O	1052	1055	and	and	CC	I-NP
O	1056	1062	desmin	desmin	NN	I-NP
O	1063	1067	than	than	IN	B-PP
O	1068	1073	those	those	DT	B-NP
O	1074	1076	in	in	IN	B-PP
O	1077	1080	the	the	DT	B-NP
O	1081	1087	vector	vector	NN	I-NP
O	1088	1096	controls	control	NNS	I-NP
O	1096	1097	.	.	.	O

O	1098	1110	Transfection	Transfection	NN	B-NP
O	1111	1115	with	with	IN	B-PP
O	1116	1119	TSP	TSP	NN	B-NP
O	1119	1120	-	-	HYPH	B-NP
O	1120	1121	1	1	CD	I-NP
O	1122	1125	and	and	CC	O
O	1126	1134	purified	purify	VBN	B-NP
O	1135	1138	TSP	TSP	NN	I-NP
O	1138	1139	-	-	HYPH	B-NP
O	1139	1140	1	1	CD	I-NP
O	1141	1146	added	add	VBN	B-VP
O	1147	1149	to	to	TO	B-PP
B-Cell	1150	1156	NIH3T3	NIH3T3	NN	B-NP
I-Cell	1157	1162	cells	cell	NNS	I-NP
O	1163	1166	did	do	VBD	B-VP
O	1167	1170	not	not	RB	I-VP
O	1171	1176	alter	alter	VB	I-VP
O	1177	1180	the	the	DT	B-NP
O	1181	1188	protein	protein	NN	I-NP
O	1189	1195	levels	level	NNS	I-NP
O	1196	1198	of	of	IN	B-PP
O	1199	1204	alpha	alpha	SYM	B-NP
O	1204	1205	-	-	HYPH	B-NP
O	1205	1208	SMA	SMA	NN	I-NP
O	1209	1212	and	and	CC	I-NP
O	1213	1219	desmin	desmin	NN	I-NP
O	1220	1223	but	but	CC	O
O	1224	1237	significantly	significantly	RB	B-VP
O	1238	1247	inhibited	inhibit	VBD	I-VP
O	1248	1254	matrix	matrix	NN	B-NP
O	1255	1270	metalloprotease	metalloprotease	NN	I-NP
O	1270	1271	-	-	HYPH	O
O	1271	1272	2	2	CD	B-NP
O	1273	1281	activity	activity	NN	I-NP
O	1281	1282	.	.	.	O

O	1283	1295	Transforming	Transform	VBG	B-NP
O	1296	1302	growth	growth	NN	I-NP
O	1303	1309	factor	factor	NN	I-NP
O	1309	1310	-	-	HYPH	O
O	1310	1314	beta	beta	SYM	B-NP
O	1315	1316	(	(	(	O
O	1316	1319	TGF	TGF	NN	B-NP
O	1319	1320	-	-	HYPH	O
O	1320	1324	beta	beta	SYM	B-NP
O	1324	1325	)	)	)	O
O	1325	1326	,	,	,	O
O	1327	1328	a	a	DT	B-NP
O	1329	1334	major	major	JJ	I-NP
O	1335	1341	factor	factor	NN	I-NP
O	1342	1344	in	in	IN	B-PP
O	1345	1348	the	the	DT	B-NP
O	1349	1359	activation	activation	NN	I-NP
O	1360	1362	of	of	IN	B-PP
B-Cell	1363	1374	fibroblasts	fibroblast	NNS	B-NP
O	1374	1375	,	,	,	O
O	1376	1385	increased	increase	VBD	B-VP
O	1386	1391	alpha	alpha	SYM	O
O	1391	1392	-	-	HYPH	O
O	1392	1395	SMA	SMA	NN	B-NP
O	1396	1399	and	and	CC	O
O	1400	1406	desmin	desmin	NN	B-NP
O	1407	1417	expression	expression	NN	I-NP
O	1418	1421	and	and	CC	O
O	1422	1425	the	the	DT	B-NP
O	1426	1433	ability	ability	NN	I-NP
O	1434	1436	of	of	IN	B-PP
B-Cell	1437	1441	cell	cell	NN	B-NP
O	1442	1451	migration	migration	NN	I-NP
O	1452	1455	and	and	CC	O
O	1456	1464	invasion	invasion	NN	B-NP
O	1465	1467	in	in	IN	B-PP
B-Cell	1468	1474	NIH3T3	NIH3T3	NN	B-NP
I-Cell	1475	1480	cells	cell	NNS	I-NP
O	1480	1481	.	.	.	O

O	1482	1485	The	The	DT	B-NP
O	1486	1495	increased	increase	VBN	I-NP
O	1496	1505	migration	migration	NN	I-NP
O	1506	1513	ability	ability	NN	I-NP
O	1514	1517	and	and	CC	O
O	1518	1521	the	the	DT	B-NP
O	1522	1530	invasive	invasive	JJ	I-NP
O	1531	1538	ability	ability	NN	I-NP
O	1539	1543	into	into	IN	B-PP
B-Cancer	1544	1549	tumor	tumor	NN	B-NP
O	1550	1557	cluster	cluster	NN	I-NP
O	1558	1560	of	of	IN	B-PP
O	1561	1564	TGF	TGF	NN	B-NP
O	1564	1565	-	-	HYPH	O
O	1565	1569	beta	beta	SYM	B-NP
O	1569	1570	-	-	HYPH	B-NP
O	1570	1577	treated	treat	VBN	I-NP
B-Cell	1578	1584	NIH3T3	NIH3T3	NN	I-NP
I-Cell	1585	1590	cells	cell	NNS	I-NP
O	1591	1595	were	be	VBD	B-VP
O	1596	1600	dose	dose	NN	B-NP
O	1601	1612	dependently	dependently	RB	B-VP
O	1613	1622	inhibited	inhibit	VBN	I-VP
O	1623	1625	by	by	IN	B-PP
O	1626	1629	TSP	TSP	NN	B-NP
O	1629	1630	-	-	HYPH	B-NP
O	1630	1631	1	1	CD	I-NP
O	1631	1632	.	.	.	O

O	1633	1635	In	In	IN	B-PP
O	1636	1644	contrast	contrast	NN	B-NP
O	1644	1645	,	,	,	O
O	1646	1653	ectopic	ectopic	JJ	B-NP
O	1654	1657	TSP	TSP	NN	I-NP
O	1657	1658	-	-	HYPH	B-NP
O	1658	1659	1	1	CD	I-NP
O	1660	1670	expression	expression	NN	I-NP
O	1671	1673	in	in	IN	B-PP
B-Cell	1674	1678	SiHa	SiHa	NN	B-NP
I-Cell	1679	1684	cells	cell	NNS	I-NP
O	1685	1688	has	have	VBZ	B-VP
O	1689	1695	little	little	JJ	B-NP
O	1696	1702	effect	effect	NN	I-NP
O	1703	1705	on	on	IN	B-PP
O	1706	1709	the	the	DT	B-NP
O	1710	1718	invasive	invasive	JJ	I-NP
O	1719	1726	ability	ability	NN	I-NP
O	1727	1729	of	of	IN	B-PP
O	1730	1733	the	the	DT	B-NP
B-Cell	1734	1740	NIH3T3	NIH3T3	NN	I-NP
I-Cell	1741	1746	cells	cell	NNS	I-NP
O	1746	1747	.	.	.	O

O	1748	1756	Together	Together	RB	B-ADVP
O	1756	1757	,	,	,	O
O	1758	1761	our	our	PRP$	B-NP
O	1762	1770	findings	finding	NNS	I-NP
O	1771	1782	demonstrate	demonstrate	VBP	B-VP
O	1783	1784	a	a	DT	B-NP
O	1785	1790	novel	novel	JJ	I-NP
O	1791	1795	role	role	NN	I-NP
O	1796	1798	of	of	IN	B-PP
O	1799	1802	TSP	TSP	NN	B-NP
O	1802	1803	-	-	HYPH	B-NP
O	1803	1804	1	1	CD	I-NP
O	1805	1807	to	to	TO	B-VP
O	1808	1815	inhibit	inhibit	VB	I-VP
B-Cancer	1816	1821	tumor	tumor	NN	B-NP
O	1821	1822	-	-	HYPH	B-NP
B-Tissue	1822	1828	stroma	stroma	NN	I-NP
O	1829	1837	reaction	reaction	NN	I-NP
O	1838	1842	that	that	WDT	B-NP
O	1843	1848	could	could	MD	B-VP
O	1849	1851	be	be	VB	I-VP
O	1852	1862	attributed	attribute	VBN	I-VP
O	1863	1865	to	to	TO	B-PP
O	1866	1869	the	the	DT	B-NP
O	1870	1878	blockage	blockage	NN	I-NP
O	1879	1881	of	of	IN	B-PP
O	1882	1891	activated	activate	VBN	B-NP
B-Cell	1892	1903	fibroblasts	fibroblast	NNS	I-NP
O	1904	1908	from	from	IN	B-PP
O	1909	1917	invading	invade	VBG	B-VP
B-Cell	1918	1924	cancer	cancer	NN	B-NP
I-Cell	1925	1930	cells	cell	NNS	I-NP
O	1930	1931	.	.	.	O

